Page last updated: 2024-12-10

4-azidophenylalanine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-azidophenylalanine: RN given refers to (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-azido-L-phenylalanine : A 4-azidophenylalanine that has L-configuration. It is used as a bioorthogonal click-chemistry reagent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

4-azidophenylalanine : A phenylalanine derivative that is phenylalanine substituted by an azido group at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3080772
SCHEMBL ID13482800
MeSH IDM0088531

Synonyms (25)

Synonym
h-p-azido-phe-oh
33173-53-4
4-azido-l-phenylalanine
l-phenylalanine, 4-azido-
AZF ,
para-azido-l-phenylalanine
4-azidophenylalanine
(2s)-2-amino-3-(4-azidophenyl)propanoic acid ,
(s)-2-amino-3-(4-azidophenyl)propanoic acid
AKOS015999214
CS-3640
SCHEMBL13482800
HY-16714
DTXSID10186829
GS-6078
J-019057
p-azidophenylalanine
(2~{s})-2-azanyl-3-(4-azidophenyl)propanoic acid
BCP18229
h-phe(4-n3)-oh
E79109
h-p-azido-l-phe-oh
p-azido-l-phenylalanine
p-azidophenylalanine;p-azido-l-phenylalanine
(s)-2-amino-3-p-azidophenylpropionic acid

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The sCAR-T-cell dosing regimen could be tuned to provide efficacy comparable to the corresponding conventional CART-19, but with lower cytokine levels, thereby offering a method of mitigating cytokine release syndrome in clinical translation."( Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
Cao, Y; Du, J; Hampton, EN; Hardy, IR; Kim, CH; Ma, J; Mazagova, M; Nunez, V; Ramadoss, NS; Rodgers, DT; Schulman, A; Schultz, PG; Shen, J; Singer, O; Wang, F; Woods, AK; Wright, TM; Young, TS, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (76)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (5.26)18.7374
1990's1 (1.32)18.2507
2000's11 (14.47)29.6817
2010's54 (71.05)24.3611
2020's6 (7.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.84 (24.57)
Research Supply Index4.34 (2.92)
Research Growth Index5.92 (4.65)
Search Engine Demand Index30.68 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other76 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]